• Join TriSalus Life Sciences for a virtual key opinion leader (KOL) event featuring Nicole Lamparello, MD (Weill Cornell Medicine, New…
    Join Equillium for a virtual key opinion leader (KOL) event where management will be joined by experts in their fields, Francisco…
    “Entering the Clinic with AX-0810: Establishing Safety, PK, and the Biomarker Roadmap for Proof of Target Engagement” Join ProQR Therapeutics…
  • Join Foghorn Therapeutics for a virtual investor event to review key development updates for its Selective ARID1B degrader program which will…
    Join SELLAS Life Sciences Group for a virtual R&D Day featuring key opinion leaders (KOLs), alongside company management, to discuss…
    Join Innate Pharma for an in-person investor and analyst event to discuss lacutamab, a Phase 3 ready asset. The program…
    Join Sensei Biotherapeutics for a virtual key opinion leader (KOL) event featuring company leadership and Kyriakos Papadopoulos, MD (Co-Director of…
    Join Corbus Pharmaceuticals for an in-person and virtual investor event featuring key opinion leaders (KOLs) Ari Rosenberg, MD (UChicago Medicine),…
    Please join Gain Therapeutics for a virtual key opinion leader (KOL) event discussing current thinking on biomarkers, clinical outcome scales,…
    Join Apyx Medical for a virtual key opinion leader (KOL) event featuring Paul Vanek, Jr., MD, FACS (Founder, President &…
    Please join Aclaris Therapeutics for its R&D Day in Midtown, New York to discuss the Company’s progress in addressing therapeutic…
    Details to follow.
    Join Eupraxia Pharmaceuticals for a webinar featuring members of company management who will discuss positive data from the highest-dose cohort…
  • Please join Ocular Therapeutix™ for its 2025 Investor Day featuring presentations from Ocular’s senior leadership and roundtable discussions with global…
    Join RESTEM for an in-person and virtual R&D Day in New York to discuss the unmet needs and current treatment…
    Join PMV Pharmaceuticals for an investor webinar to review the interim PYNNACLE Phase 2 data and provide a regulatory update.…